We next performed orthotopic cell transplantation experiments to determine whether the ASCL1-mediated neuronal reprogramming could inhibit the tumorigenic potential of human glioma cells in vivo (Figure 8A). This evidence concerns the gene ASCL1 and central nervous system cancer.